475 related articles for article (PubMed ID: 33339292)
1. The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents.
Coll-Martínez B; Delgado A; Crosas B
Molecules; 2020 Dec; 25(24):. PubMed ID: 33339292
[TBL] [Abstract][Full Text] [Related]
2. Targeted protein degradation: A promise for undruggable proteins.
Samarasinghe KTG; Crews CM
Cell Chem Biol; 2021 Jul; 28(7):934-951. PubMed ID: 34004187
[TBL] [Abstract][Full Text] [Related]
3. Advancement of targeted protein degradation strategies as therapeutics for undruggable disease targets.
Kannan MP; Sreeraman S; Somala CS; Kushwah RB; Mani SK; Sundaram V; Thirunavukarasou A
Future Med Chem; 2023 May; 15(10):867-883. PubMed ID: 37254917
[TBL] [Abstract][Full Text] [Related]
4. Expanding the ligand spaces for E3 ligases for the design of protein degraders.
Shah Zaib Saleem R; Schwalm MP; Knapp S
Bioorg Med Chem; 2024 May; 105():117718. PubMed ID: 38621319
[TBL] [Abstract][Full Text] [Related]
5. Redefining the Scope of Targeted Protein Degradation: Translational Opportunities in Hijacking the Autophagy-Lysosome Pathway.
Cassidy K; Zhao H
Biochemistry; 2023 Feb; 62(3):580-587. PubMed ID: 34569233
[TBL] [Abstract][Full Text] [Related]
6. Bardoxolone conjugation enables targeted protein degradation of BRD4.
Tong B; Luo M; Xie Y; Spradlin JN; Tallarico JA; McKenna JM; Schirle M; Maimone TJ; Nomura DK
Sci Rep; 2020 Sep; 10(1):15543. PubMed ID: 32968148
[TBL] [Abstract][Full Text] [Related]
7. Breaking Bad Proteins-Discovery Approaches and the Road to Clinic for Degraders.
Bouvier C; Lawrence R; Cavallo F; Xolalpa W; Jordan A; Hjerpe R; Rodriguez MS
Cells; 2024 Mar; 13(7):. PubMed ID: 38607017
[TBL] [Abstract][Full Text] [Related]
8. Bifunctional Peptide Nanofibrils for Targeted Protein Degradation.
Lin Z; Garcia BA; Lv D
Angew Chem Int Ed Engl; 2024 Jan; 63(3):e202316581. PubMed ID: 38059785
[TBL] [Abstract][Full Text] [Related]
9. Degraders upgraded: the rise of PROTACs in hematological malignancies.
Casan JML; Seymour JF
Blood; 2024 Mar; 143(13):1218-1230. PubMed ID: 38170175
[TBL] [Abstract][Full Text] [Related]
10. Extracellular targeted protein degradation: an emerging modality for drug discovery.
Wells JA; Kumru K
Nat Rev Drug Discov; 2024 Feb; 23(2):126-140. PubMed ID: 38062152
[TBL] [Abstract][Full Text] [Related]
11. Targeted protein degradation directly engaging lysosomes or proteasomes.
Kim J; Byun I; Kim DY; Joh H; Kim HJ; Lee MJ
Chem Soc Rev; 2024 Apr; 53(7):3253-3272. PubMed ID: 38369971
[TBL] [Abstract][Full Text] [Related]
12. Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery.
Burslem GM; Crews CM
Cell; 2020 Apr; 181(1):102-114. PubMed ID: 31955850
[TBL] [Abstract][Full Text] [Related]
13. Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety.
Zhang R; Xie S; Ran J; Li T
J Cell Physiol; 2024 May; 239(5):e31255. PubMed ID: 38501341
[TBL] [Abstract][Full Text] [Related]
14. Applications of protein ubiquitylation and deubiquitylation in drug discovery.
Chen Y; Xue H; Jin J
J Biol Chem; 2024 May; 300(5):107264. PubMed ID: 38582446
[TBL] [Abstract][Full Text] [Related]
15. Novel approaches to targeted protein degradation technologies in drug discovery.
Xue Y; Bolinger AA; Zhou J
Expert Opin Drug Discov; 2023 Apr; 18(4):467-483. PubMed ID: 36895136
[TBL] [Abstract][Full Text] [Related]
16. Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins.
Lin J; Jin J; Shen Y; Zhang L; Gong G; Bian H; Chen H; Nagle DG; Wu Y; Zhang W; Luan X
Theranostics; 2021; 11(17):8337-8349. PubMed ID: 34373745
[TBL] [Abstract][Full Text] [Related]
17. Small molecule induced STING degradation facilitated by the HECT ligase HERC4.
Mutlu M; Schmidt I; Morrison AI; Goretzki B; Freuler F; Begue D; Simic O; Pythoud N; Ahrne E; Kapps S; Roest S; Bonenfant D; Jeanpierre D; Tran TT; Maher R; An S; Rietsch A; Nigsch F; Hofmann A; Reece-Hoyes J; Parker CN; Guerini D
Nat Commun; 2024 May; 15(1):4584. PubMed ID: 38811577
[TBL] [Abstract][Full Text] [Related]
18. Protein degradation technology: a strategic paradigm shift in drug discovery.
Li H; Dong J; Cai M; Xu Z; Cheng XD; Qin JJ
J Hematol Oncol; 2021 Sep; 14(1):138. PubMed ID: 34488823
[TBL] [Abstract][Full Text] [Related]
19. Alkenyl oxindole is a novel PROTAC moiety that recruits the CRL4DCAF11 E3 ubiquitin ligase complex for targeted protein degradation.
Wang Y; Wei T; Zhao M; Huang A; Sun F; Chen L; Lin R; Xie Y; Zhang M; Xu S; Sun Z; Hong L; Wang R; Tian R; Li G
PLoS Biol; 2024 May; 22(5):e3002550. PubMed ID: 38768083
[TBL] [Abstract][Full Text] [Related]
20. Targeted protein degradation might present a novel therapeutic approach in the fight against African trypanosomiasis.
Danazumi AU; Ishmam IT; Idris S; Izert MA; Balogun EO; Górna MW
Eur J Pharm Sci; 2023 Jul; 186():106451. PubMed ID: 37088149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
